2020-07-15T10:31:06-05:00 2019-06-30 390859910 BAKER TILLY VIRCHOW KRAUSE LLP 1570 FRUITVILLE PIKE SUITE 400 LANCASTER PA 17601 990 2018-07-01 210672684 CORIELL INSTITUTE FOR MEDICAL RESEARCH INC CORI 8567574828 403 HADDON AVENUE CAMDEN NJ 08103 CONSTANTINE STOIOS CFO 8567574828 2020-07-14 1 KERRI N BOGDA CPA P00760402 7177404863 73.187.220.225 2020-07-14 12:46:34 ED P DA39A3EE5E6B4B0D3255BFEF95601890AFD80709 BF90B4BE16E9AE312C0D8383967EBAED4A365E8B 2018 2020-09-23 17:36:50Z CONSTANTINE STOIOS 403 HADDON AVENUE CAMDEN NJ 08103 16900057 0 X WWW.CORIELL.ORG X 1953 NJ GENERATE WORLD CLASS BIOMATERIALS AND CONDUCT GROUNDBREAKING RESEARCH. 13 12 135 14 0 0 1302270 1275612 15329456 14701499 465293 237157 1004037 20102 18101056 16234370 0 0 0 0 10233701 9828445 0 0 38134 8466305 8067177 18700006 17895622 -598950 -1661252 29566205 29705452 7931971 6639367 21634234 23066085 X CORIELL'S MISSION IS TO ACCELERATE SCIENTIFIC DISCOVERY BY GENERATING WORLD-CLASS BIOMATERIALS AND CONDUCTING GROUNDBREAKING RESEARCH IN PERSONALIZED MEDICINE AND STEM CELL BIOLOGY. 0 0 11662107 0 14701499 CORIELL INSTITUTE FOR MEDICAL RESEARCH, FOUNDED IN 1953 AND BASED IN CAMDEN, NEW JERSEY, IS AN INDEPENDENT NON-PROFIT RESEARCH INSTITUTE DEDICATED TO THE STUDY OF THE HUMAN GENOME. EXPERT STAFF AND PIONEERING PROGRAMS IN THE FIELDS OF PERSONALIZED MEDICINE, CELL BIOLOGY, CYTOGENETICS, GENOTYPING, AND BIOBANKING DRIVE OUR MISSION. THE INSTITUTE MAINTAINS REPOSITORIES FOR CELL LINES AND DNA AND DISTRIBUTES OVER 20,000 BIOMATERIALS ANNUALLY TO RESEARCHERS NATIONALLY AND INTERNATIONALLY.THE CORIELL PERSONALIZED MEDICINE COLLABORATIVE (CPMC) RESEARCH STUDY IS SEEKING TO UNDERSTAND THE USEFULNESS OF GENETIC RISK AND PHARMACOGENOMICS IN CLINICAL DECISION-MAKING AND HEALTHCARE MANAGEMENT.CORIELL HAS A DISTINGUISHED HISTORY IN CELL BIOLOGY, PURSUING CURRENTLY INDUCED PLURIPOTENT STEM (IPS) CELL RESEARCH. THESE POWERFUL CELLS ARE REVOLUTIONIZING THE WAY HUMAN DISEASE IS STUDIED AND HOW DRUGS ARE DEVELOPED. CORIELL OFFERS CUSTOM RESEARCH SERVICES INCLUDING CELL CULTURE, CYTOGENETIC ANALYSES, AND MOLECULAR BIOLOGY. ITS CLIA-CERTIFIED GENOTYPING AND MICROARRAY CENTER OFFERS HIGH-THROUGHPUT DNA ANALYSIS SYSTEMS USING THE PLATFORMS OF TWO LEADING PROVIDERS.ESSENTIAL TO THE INSTITUTE'S SUPPORT OF INTERNATIONAL SCIENTIFIC RESEARCH IS THE CORIELL BIOBANK. FROM THIS RENOWNED CELL BANK, CORIELL MANAGES AND DISTRIBUTES THE WORLD'S MOST DIVERSE COLLECTION OF CELL LINES, DNA, AND OTHER BIOLOGICAL RESOURCES. THE CORIELL BIOBANK PROVIDED SUPPORT TO THE HUMAN GENOME PROJECT, A WORLDWIDE PROGRAM TO MAP THE ENTIRE HUMAN GENOME, AND TO THE INTERNATIONAL HAPMAP PROJECT, A PROJECT PROVIDING AN EFFICIENT TOOL TO IDENTIFY DISEASE-CAUSING GENES.CORIELL'S BIOBANKING OPERATION IS FUNDED BY SEVERAL NATIONAL INSTITUTE OF HEALTH AWARDS. 11662107 1 1 0 1 0 0 0 0 0 1 1 0 1 1 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 44 0 135 1 0 0 0 0 0 0 0 0 0 0 0 0 X 13 12 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 1 1 NJ PA NY CA X DENISE BUSCHER CONTROLLER 8567574846 403 HADDON AVENUE CAMDEN NJ 08103 ARNAUD BASTIEN MD TRUSTEE 1.00 X 0 0 0 CHARLES LORD TRUSTEE 1.00 X 0 0 0 EDWARD VINER MD TRUSTEE 1.00 X 0 0 0 FRANK GIORDANO TRUSTEE 1.00 X 0 0 0 GEORGE NORCROSS TRUSTEE 1.00 X 0 0 0 JOHN PICCONE TRUSTEE 1.00 X 0 0 0 MARC MASER ESQ VICE CHAIR 1.00 X X 0 0 0 PETER DRISCOLL ESQ TRUSTEE 1.00 X 0 0 0 ROBERT KIEP III CHAIR 1.00 X X 0 0 0 ROLAND SCHWARTING TRUSTEE 1.00 X 0 0 0 DR JEAN-PIERRE ISSA PRES. & CEO/SECRETARY(AS OF 2/2019) 40.00 X X 0 0 0 CHRISTOPHER GIBSON TRUSTEE 1.00 X 0 0 0 DANA REDD TRUSTEE 1.00 X 0 0 0 ALISSA RESCH CHIEF SCIENTIFIC OFFICER 40.00 X 210897 0 21906 CONSTANTINE DEAN STOIOS CHIEF FINANCIAL OFFICER/TREASURER 40.00 X 253591 0 40272 MARK BELLAFANTE CHIEF INFORMATION OFFICER 40.00 X 230727 0 41000 NAHID TURAN CHIEF LABORATORY OFFICER 40.00 X 183534 0 21188 COURTNEY DIRKS DIRECTOR, PUBLIC RELATIONS 40.00 X 139343 0 34339 JOSEPH JARVIS DIRECTOR, GENOMIC RISK REPORT 40.00 X 119296 0 15239 LEO JOSE DIRECTOR, APPLICATION DEVELOPMENT 40.00 X 145420 0 34917 STEFAN ZAJIC PRINCIPAL RESEARCH SCIENTIST 40.00 X 136568 0 24242 PAN ZHANG DIR., SEQUENCING & MICROARRY CENTER 40.00 X 122079 0 16732 1541455 0 249835 14 0 1 0 CELLULAR DYNAMICS INTERNATIONAL 603 SCIENCE DRIVE MADISON WI 53711 SCIENTIFIC SERVICES 578035 KORNFERRY INTERNATIONAL 1650 ARCH STREET STE 200 PHILADELPHIA PA 19103 EXECUTIVE RECRUITER 178704 2 2498 1037000 236114 1275612 GOVT FEES & CONTRACTS 621500 12463754 12463754 NON-GOVERNMENT REPOSITORY SERVICE 621500 2228645 2228645 INVESTIGATOR DIRECTED SCIENCE 621500 9100 9100 14701499 84624 84624 818220 652788 12899 165432 -12899 152533 152533 LIFE INSURANCE PROCEEDS 900099 20102 20102 20102 16234370 14701499 0 257259 541423 541423 6894074 5303910 1590164 396000 350740 45260 1474812 910200 564612 522136 371425 150711 149667 149667 120705 120705 65712 65712 1092639 356484 698021 38134 2052696 2043971 8725 2597424 1102173 1495251 220007 72494 147513 1768327 1150710 617617 17895622 11662107 6195381 38134 1200 1200 154044 180470 4381042 3167888 538763 655785 73500 0 158461 59726 356569 323081 31720405 23552935 8737340 8167470 3291341 2002448 3360000 11873945 11787384 29566205 29705452 1618963 1238839 222376 157549 5680376 5178514 410256 64465 7931971 6639367 X 9536880 13752093 11280776 8497414 816578 816578 21634234 23066085 29566205 29705452 X -1661252 -180315 -48 3273466 X 0 1 X 1 1 1 X 1298301 1420848 1120670 1302270 1275612 6417701 1298301 1420848 1120670 1302270 1275612 6417701 19 6417682 216365 174582 157614 99486 84624 732671 2223 36 78821 1004037 20102 1105219 8255591 82675156 0.77740 0.79380 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2014 AMOUNT: $ 2,223. 2015 AMOUNT: $ 36. 2016 AMOUNT: $ 1,435. COMMERCIAL RECEIPTS HOLDING REV - 2016 AMOUNT: $ 77,386. LIFE INSURANCE PROCEEDS - 2017 AMOUNT: $ 1,004,037. 2018 AMOUNT: $ 20,102. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 65712 65712 17829910 17895622 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 44750 43978 44583 65712 199023 250000 250000 250000 250000 1000000 1500000 3291341 0 61107 1350000 2002448 4391456 11468 388417 1500000 3291341 5769781 8507 913168 2300000 4391456 7717138 1237 -448594 1500000 5769781 7634237 6339 76562 7717138 0.03220 0.40780 0.56000 0 0 245000 245000 14444124 10656493 3787631 1725594 1497080 228514 15305687 11399362 3906325 8167470 NONCONTROLLING INTEREST IN CLS 3360000 C 3360000 NEW JERSEY CORD BLOOD BANK 4675500 USE OF RESEARCH FACILITY 6429164 SPLIT-INTEREST AGREEMENTS 678534 OTHER MISCELLANEOUS ASSETS 4185 11787383 ADVANCES ON HAND 10127 HOLDING ACCOUNTS 432 OVER-RECOVERY INDIRECT COSTS 53906 64465 X 23712512 -180315 652275 7006182 7478142 16234370 0 16234370 20076741 652275 1528844 2181119 17895622 0 17895622 PART V, LINE 4: THE INSTITUTE'S ENDOWMENT FUNDS ARE USED TO SUPPORT THE SHORT AND LONG TERM GOALS OF THE INSTITUTE. THE INSTITUTE DREW $1,350,000 OF FUNDS FROM THE ENDOWMENT DURING THE YEAR ENDING JUNE 30, 2019. PART X, LINE 2: THE INSTITUTE ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES USING A RECOGNITION THRESHOLD OF MORE-LIKELY-THAN-NOT TO BE SUSTAINED UPON EXAMINATION BY THE APPROPRIATE TAXING AUTHORITY. MEASUREMENT OF THE TAX UNCERTAINTY OCCURS IF THE RECOGNITION THRESHOLD HAS BEEN MET. MANAGEMENT DETERMINED THAT THERE WERE NO TAX UNCERTAINTIES THAT MET THE RECOGNITION THRESHOLD IN 2019 AND 2018. PART XI, LINE 2D - OTHER ADJUSTMENTS: CHANGE IN VALUE OF SPLIT-INTEREST AGREEMENTS 25,933. CHANGE IN VALUE OF FUTURE BUILDING OCCUPANCY -112,581. CHANGE IN VALUE OF DERIVATIVE FINANCIAL INSTRUMENT 115. CORIELL LIFE SCIENCES NON-CONTROLLING INTERESTS 637,087. CORIELL LIFE SCIENCES INVESTOR CONTRIBUTIONS 650,000. GAIN ON DECONSOLIDATION OF NET ASSETS 4,573,893. CORIELL LIFE SCIENCE REVENUE 1,231,735. PART XII, LINE 2D - OTHER ADJUSTMENTS: CORIELL LIFE SCIENCE EXPENSES 1,528,844. X X X X 0 0 0 0 0 0 0 1 0 ALISSA RESCH CHIEF SCIENTIFIC OFFICER 165897 0 45000 0 0 0 14831 0 7075 0 232803 0 0 0 CONSTANTINE DEAN STOIOS CHIEF FINANCIAL OFFICER/TREASURER 198591 0 55000 0 0 0 18550 0 21722 0 293863 0 0 0 MARK BELLAFANTE CHIEF INFORMATION OFFICER 185727 0 45000 0 0 0 16800 0 24200 0 271727 0 0 0 NAHID TURAN CHIEF LABORATORY OFFICER 143534 0 40000 0 0 0 12950 0 8238 0 204722 0 0 0 COURTNEY DIRKS DIRECTOR, PUBLIC RELATIONS 132343 0 7000 0 0 0 10390 0 23949 0 173682 0 0 0 LEO JOSE DIRECTOR, APPLICATION DEVELOPMENT 143420 0 2000 0 0 0 10913 0 24004 0 180337 0 0 0 STEFAN ZAJIC PRINCIPAL RESEARCH SCIENTIST 134568 0 2000 0 0 0 10249 0 13993 0 160810 0 0 0 PART I, LINE 7 THE COMPENSATION COMMITTEE DETERMINES BONUSES FOR OFFICERS AND KEY EMPLOYEES BASED UPON VARIOUS PERFORMANCE CRITERIA. PERFORMANCE CRITERIA ARE BASED ON VARIOUS OBJECTIVES, SOME OF WHICH ARE BASED ON BUSINESS/ FINANCIAL GOALS. OVERALL, THE PRIMARY OBJECTIVES ARE OPERATIONAL IN NATURE WITH CONSIDERATION GIVEN TO FINANCIAL OUTCOMES. FORM 990, PART VI, SECTION A, LINE 1 THERE ARE 9 BOARD MEMBERS ON THE EXECUTIVE COMMITTEE. WITH THE EXCEPTION OF THE PRESIDENT AND CEO, THE OTHER BOARD MEMBERS OF THE EXECUTIVE COMMITTEE ARE NON-EMPLOYED VOLUNTARY BOARD MEMBERS. THE EXECUTIVE COMMITTEE MAY ACT ON BEHALF OF THE BOARD OF TRUSTEES WHEN THE BOARD IS NOT IN SESSION. FORM 990, PART VI, SECTION B, LINE 11B THE CONTROLLER INITIALLY PERFORMS A THOROUGH REVIEW OF THE FORM 990 AND THEN THE CFO PROVIDES A SECOND REVIEW. ONCE APPROVED AFTER INTERNAL REVIEW, THE CHAIR OF THE AUDIT COMMITTEE REVIEWS THE FORM 990 AND PRESENTS ITS CONTENTS TO MEMBERS OF THE AUDIT AND EXECUTIVE COMMITTEES. THE FORM IS DISTRIBUTED TO ALL CORIELL TRUSTEES BEFORE FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE CEO ANNUALLY DISTRIBUTES THE CONFLICT OF INTEREST POLICY AND DISCLOSURE STATEMENT TO EACH MEMBER OF THE BOARD OF TRUSTEES. EACH TRUSTEE MUST COMPLETE AND RETURN THE ANNUAL DISCLOSURE STATEMENT TO THE CEO ON A TIMELY BASIS. HE OR SHE MUST TIMELY INFORM THE CEO AND/OR THE COMMITTEE OF ANY POTENTIAL OR ACTUAL CONFLICT OF INTEREST OR OF ANY SITUATION WHICH MIGHT LEAD TO THE APPEARANCE OF A CONFLICT OF INTEREST. IN ADDITION, THE CHIEF FINANCIAL OFFICER (CFO) ANNUALLY DISTRIBUTES A COPY OF THE EMPLOYEE CONFLICT OF INTEREST POLICY AND DISCLOSURE STATEMENT TO EACH OFFICER, EXECUTIVE, AND APPROPRIATE EMPLOYEE. THESE EMPLOYEES ARE REQUIRED TO SUBMIT THE COMPLETED DISCLOSURE STATEMENT TO THE CFO AND DISCLOSE ANY POTENTIAL OR ACTUAL CONFLICT OF INTEREST. REPORTED CONFLICTS OF INTEREST ARE SHARED WITH THE EXECUTIVE COMMITTEE. ANY BOARD MEMBER WHO HAS A CONFLICT OF INTEREST IS EXCLUDED FROM VOTING ON ANY ISSUE INVOLVING THE CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 USING COMPARABILITY DATA SOURCED FROM AN INDEPENDENT ORGANIZATION, A BOARD OF TRUSTEES' COMPENSATION COMMITTEE REVIEWS THE PERFORMANCE AND ESTABLISHES THE ANNUAL COMPENSATION FOR THE CHIEF EXECUTIVE OFFICER. COMPENSATION DECISIONS ARE DETERMINED BY TAKING INTO CONSIDERATION THE FAIR MARKET RANGE FOR THE INDUSTRY. ALL COMMITTEE DISCUSSIONS ARE DOCUMENTED IN BOARD MINUTES. THE PRESIDENT DETERMINES THE COMPENSATION ANNUALLY FOR ALL OTHER EMPLOYEES, INCLUDING OFFICERS AND KEY EMPLOYEES, BASED ON PERFORMANCE APPRAISALS AND REVIEWS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XI, LINE 9: CHANGE IN VALUE OF SPLIT-INTEREST AGREEMENTS 25,933. CHANGE IN VALUE OF FUTURE BUILDING OCCUPANCY -112,581. CHANGE IN FAIR VALUE OF DERIVATIVE FINANCIAL INSTRUMENT 115. CORIELL LIFE SCIENCES NET ASSETS -1,213,894. GAIN ON DECONSOLIDATION OF NET ASSETS 4,573,893. CORIELL LIFE SCIENCES 403 HADDON AVENUE CAMDEN NJ 08103 461794812 GENETIC DATA STORAGE AND INTERPRETATION DE N/A C -494061 3241517 0.39880 1 0 0 0 1 0 0 0 0 0 0 1 0 1 1 1 0 1 0 0 THIS FORM 990 IS BEING FILED LATE DUE TO AN INADVERTENT OMISSION ON THE PART OF THE INDEPENDENT ACCOUNTING FIRM. TECHNICAL FAILURES RELATED TO SOFTWARE WHICH KEEPS TRACK OF FILINGS LED TO THE INADVERTENT INACTION IN FILING THE REQUISITE EXTENSIONS. BOTH THE ORGANIZATION AND ITS ACCOUNTING FIRM RECOGNIZE THE IMPORTANCE OF FILING ALL RETURN REQUIREMENTS TIMELY AND THIS OMISSION IS A RARE OMISSON THAT HAS BEEN NOTED. CHANGES TO THE PROCESS HAVE BEEN ESTABLISHED TO ENSURE THAT FUTURE FILINGS ARE ALL CAPTURED INTERNALLY SO THAT TIMELY FILINGS CAN BE MADE.